Genmab to Submit Supplemental Biologics License Application (sBLA) to U.S. Food and Drug Administration for Epcoritamab Plus Rituximab and Lenalidomide (R2) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)
Genmab announces plans to submit a supplemental Biologics License Application to the FDA for a combination therapy targeting relapsed or refractory follicular lymphoma, potentially offering new hope to patients.
4 months ago
2 mins read